Hot Topics in Pharmacology

Coronavrius Information

We are currently collating information related to SARS-CoV-2 and COVID-19 at a dedicated coronavirus information page. This contains details of ligands and targets relevant to COVID-19 and links to useful resources and publications.

Recent publications of interest recommended by NC-IUPHAR

2021: May | Apr | Mar | Feb | Jan
2020: Dec | Nov | Oct | Sep | Aug | Jul | Jun | May

    May 2021


  • Will the chemical probes please stand up?.
    Škuta C, Southan C, Bartůněk P. Will the chemical probes please stand up?. (2021)  ChemRxiv, Preprint. DOI: 10.26434/chemrxiv.14511666.v1

  • April 2021


  • RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape.
    Mullard A. RECOVERY 1 year on: a rare success in the COVID-19 clinical trial landscape. (2021)  Nat Rev Drug Discov, [Epub ahead of print]. [PMID:33864035]

  • Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19.
    Gaziano L, Giambartolomei C, Pereira AC, Gaulton A, Posner DC, Swanson SA, Ho YL, Iyengar SK, Kosik NM, Vujkovic M et al.. Actionable druggable genome-wide Mendelian randomization identifies repurposing opportunities for COVID-19. (2021)  Nat Med, 27 (4): 668-676. [PMID:33837377]

  • The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice.
    Dekeryte R, Franklin Z, Hull C, Croce L, Kamli-Salino S, Helk O, Hoffmann PA, Yang Z, Riedel G, Delibegovic M et al.. The BACE1 inhibitor LY2886721 improves diabetic phenotypes of BACE1 knock-in mice. (2021)  Biochim Biophys Acta Mol Basis Dis, 1867 (7): 166149 [Epub ahead of print]. [PMID:33892080]

  • Novel drug targets in 2020.
    Avram S, Halip L, Curpan R, Oprea TI. Novel drug targets in 2020. (2021)  Nat Rev Drug Discov, [Epub ahead of print]. [PMID:33824485]

  • The Promise and Peril of Chemical Probe Negative Controls.
    Lee J, Schapira M. The Promise and Peril of Chemical Probe Negative Controls. (2021)  ACS Chem Biol, [Epub ahead of print]. [PMID:33745272]

  • Road to effective data curation for translational research.
    Gu W, Hasan S, Rocca-Serra P, Satagopam VP. Road to effective data curation for translational research. (2021)  Drug Discov Today, 26 (3): 626-630. [PMID:33338655]

  • The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscape.
    Fraser N, Brierley L, Dey G, Polka JK, Pálfy M, Nanni F, Coates JA. The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscape. (2021)  PLoS Biol, 19 (4): e3000959 [Epub ahead of print]. [PMID:33798194]

  • A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells.
    Mellott DM, Tseng CT, Drelich A, Fajtová P, Chenna BC, Kostomiris DH, Hsu J, Zhu J, Taylor ZW, Kocurek KI et al.. A Clinical-Stage Cysteine Protease Inhibitor blocks SARS-CoV-2 Infection of Human and Monkey Cells. (2021)  ACS Chem Biol, 16 (4): 642-650. [PMID:33787221]

  • COVID vaccines and blood clots: five key questions
    Ledford H. COVID vaccines and blood clots: five key questions. (2021)  Nature, 592 (7855): 495-496. [PMID:33864049]
    Ledford H. How could a COVID vaccine cause blood clots? Scientists race to investigate. (2021)  Nature, 592 (7854): 334-335. [PMID:33846607]

  • Biden pursues giant boost for science spending.
    Tollefson J, Maxmen A, Remmel A, Subbaraman N, Witze A. Biden pursues giant boost for science spending. 
    Accessed on 12/04/2021. Modified on 12/04/2021. Nature, https://www.nature.com/articles/d41586-021-00897-0. DOI: 10.1038/d41586-021-00897-0

  • Structural insights into the lipid and ligand regulation of serotonin receptors.
    Xu P, Huang S, Zhang H, Mao C, Zhou XE, Cheng X, Simon IA, Shen DD, Yen HY, Robinson CV et al.. Structural insights into the lipid and ligand regulation of serotonin receptors. (2021)  Nature, [Epub ahead of print]. [PMID:33762731]

  • March 2021


  • The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans.
    Smith BAH, Bertozzi CR. The clinical impact of glycobiology: targeting selectins, Siglecs and mammalian glycans. (2021)  Nat Rev Drug Discov, 20 (3): 217-243. [PMID:33462432]

  • Signals of hope: gauging the impact of a rapid national vaccination campaign.
    Shilo S, Rossman H, Segal E. Signals of hope: gauging the impact of a rapid national vaccination campaign. (2021)  Nat Rev Immunol, [Epub ahead of print]. [PMID:33712744]

  • AI and Drug Discovery: Attacking the Right Problems
    Bender A, Cortes-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 2: a discussion of chemical and biological data. (2021)  Drug Discov Today, [Epub ahead of print]. [PMID:33508423]
    Bender A, Cortés-Ciriano I. Artificial intelligence in drug discovery: what is realistic, what are illusions? Part 1: Ways to make an impact, and why we are not there yet. (2021)  Drug Discov Today, 26 (2): 511-524. [PMID:33346134]
    Lowe D. AI and Drug Discovery: Attacking the Right Problems.  In the Pipeline, https://blogs.sciencemag.org/pipeline/archives/2021/03/19/ai-and-drug-discovery-attacking-the-right-problems

  • Structural insights into the human D1 and D2 dopamine receptor signaling complexes.
    Zhuang Y, Xu P, Mao C, Wang L, Krumm B, Zhou XE, Huang S, Liu H, Cheng X, Huang XP et al.. Structural insights into the human D1 and D2 dopamine receptor signaling complexes. (2021)  Cell, 184 (4): 931-942.e18. [PMID:33571431]

  • Trends in COVID-19 therapeutic clinical trials.
    Bugin K, Woodcock J. Trends in COVID-19 therapeutic clinical trials. (2021)  Nat Rev Drug Discov, [Epub ahead of print]. [PMID:33633370]

  • Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system.
    Yeung ML, Teng JLL, Jia L, Zhang C, Huang C, Cai JP, Zhou R, Chan KH, Zhao H, Zhu Let al.. Soluble ACE2-mediated cell entry of SARS-CoV-2 via interaction with proteins related to the renin-angiotensin system. (2021)  Cell, Preprint. DOI: 10.1016/j.cell.2021.02.053

  • February 2021


  • Constitutive G protein coupling profiles of understudied orphan GPCRs.
    Lu S, Jang W, Inoue A, Lambert NA. Constitutive G protein coupling profiles of understudied orphan GPCRs.   bioRxiv, Preprint. DOI: 10.1101/2021.02.16.431425

  • Structure and inhibition mechanism of the human citrate transporter NaCT.
    Sauer DB, Song J, Wang B, Hilton JK, Karpowich NK, Mindell JA, Rice WJ, Wang DN. Structure and inhibition mechanism of the human citrate transporter NaCT. (2021)  Nature, [Epub ahead of print]. [PMID:33597751]

  • Structures of the human dopamine D3 receptor-Gi complexes.
    Xu P, Huang S, Mao C, Krumm BE, Zhou XE, Tan Y, Huang XP, Liu Y, Shen DD, Jiang Y et al.. Structures of the human dopamine D3 receptor-Gi complexes. (2021)  Mol Cell, [Epub ahead of print]. [PMID:33548201]

  • Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites.
    Dorjsuren D, Eastman RT, Wicht KJ, Jansen D, Talley DC, Sigmon BA, Zakharov AV, Roncal N, Girvin AT, Antonova-Koch Y et al.. Chemoprotective antimalarials identified through quantitative high-throughput screening of Plasmodium blood and liver stage parasites. (2021)  Sci Rep, 11 (1): 2121. [PMID:33483532]

  • Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations.
    Tree JA, Turnbull JE, Buttigieg KR, Elmore MJ, Coombes N, Hogwood J, Mycroft-West CJ, Lima MA, Skidmore MA, Karlsson R et al.. Unfractionated heparin inhibits live wild type SARS-CoV-2 cell infectivity at therapeutically relevant concentrations. (2021)  Br J Pharmacol, 178 (3): 626-635. [PMID:33125711]

  • Identification of the core chemical structure in SureChEMBL patents.
    Falaguera MJ, Mestres J. Identification of the core chemical structure in SureChEMBL patents. (2021)  chemRxiv, Preprint. DOI: 10.26434/chemrxiv.13660994.v1

  • SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor.
    Zahradník J, Marciano S, Shemesh M, Zoler E, Chiaravalli J, Meyer B, Rudich Y, Dym O, Elad N, Schreiber G. SARS-CoV-2 RBD in vitro evolution follows contagious mutation spread, yet generates an able infection inhibitor. (2021)  bioRxiv, Preprint. DOI: 10.1101/2021.01.06.425392

  • January 2021


  • CoV3D: a database of high resolution coronavirus protein structures.
    Gowthaman R, Guest JD, Yin R, Adolf-Bryfogle J, Schief WR, Pierce BG. CoV3D: a database of high resolution coronavirus protein structures. (2021)  Nucleic Acids Res, 49 (D1): D282-D287. [PMID:32890396]

  • Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies.
    Greaney AJ, Loes AN, Crawford KHD, Starr TN, Malone KD, Chu HY, Bloom JD. Comprehensive mapping of mutations to the SARS-CoV-2 receptor-binding domain that affect recognition by polyclonal human serum antibodies. (2021)  bioRxiv, Preprint. DOI: 10.1101/2020.12.31.425021

  • The cellular immune response to COVID-19 deciphered by single cell multi-omics across three UK centres.
    Stephenson E, Reynolds G, Botting RA, Calero-Nieto FJ, Morgan M, Tuong ZK, Bach K, Sungnak W, Worlock KB, Yoshida M et al.. The cellular immune response to COVID-19 deciphered by single cell multi-omics across three UK centres. (2021)  MedRxiv, Preprint. DOI: 10.1101/2021.01.13.21249725

  • The role of orphan receptor GPR139 in neuropsychiatric behavior.
    Dao M, Stoveken HM, Cao Y, Martemyanov KA. The role of orphan receptor GPR139 in neuropsychiatric behavior. (2021)  Neuropsychopharmacology, [Epub ahead of print]. [PMID:33479510]

  • Hot Topics: Gene Symbol usage and the need to do better

    Comments by Chris Southan, Fellow of the University of Edinburgh, Owner of TW2Informatics, Chair of NC-IUPHAR Subcommitees for Proteases and Drug Targets and Chemistry (DRUTACS).

    The GtoPdb team need no convincing about the importance of ameliorating equivocality in gene and gene product names, both as they are used (often incorrectly) in the pharmacology and drug discovery literature. Crucially, this also applies to their inclusion in curated database records such as GtoPdb.. Read the full article on our blog

  • Integrating lipidomics and genomics: emerging tools to understand cardiovascular diseases.
    Tabassum R, Ripatti S. Integrating lipidomics and genomics: emerging tools to understand cardiovascular diseases. (2021)  Cell Mol Life Sci, [Epub ahead of print]. [PMID:33449144]

  • The influence of evolutionary history on human health and disease.
    Benton ML, Abraham A, LaBella AL, Abbot P, Rokas A, Capra JA. The influence of evolutionary history on human health and disease. (2021)  Nat Rev Genet, [Epub ahead of print]. [PMID:33408383]

  • Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK.
    du Plessis L, McCrone JT, Zarebski AE, Hill V, Ruis C, Gutierrez B, Raghwani J, Ashworth J, Colquhoun R, Connor TR et al.. Establishment and lineage dynamics of the SARS-CoV-2 epidemic in the UK. (2021)  Science, 371 (6530): 708-712. [PMID:33419936]

  • Evolution of the endothelin pathway drove neural crest cell diversification.
    Square TA, Jandzik D, Massey JL, Romášek M, Stein HP, Hansen AW, Purkayastha A, Cattell MV, Medeiros DM. Evolution of the endothelin pathway drove neural crest cell diversification. (2020)  Nature, 585 (7826): 563-568. [PMID:32939088]

  • December 2020


  • Genetic mechanisms of critical illness in COVID-19.
    Pairo-Castineira E, Clohisey S, Klaric L, Bretherick AD, Rawlik K, Pasko D, Walker S, Parkinson N, Fourman MH, Russell CD et al.. Genetic mechanisms of critical illness in COVID-19. (2021)  Nature, 591 (7848): 92-98. [PMID:33307546]

  • KCNE1 is an auxiliary subunit of two distinct ion channel superfamilies.
    Ávalos Prado P, Häfner S, Comoglio Y, Wdziekonski B, Duranton C, Attali B, Barhanin J, Sandoz G. KCNE1 is an auxiliary subunit of two distinct ion channel superfamilies. (2021)  Cell, 184 (2): 534-544.e11. [PMID:33373586]

  • 'It will change everything': DeepMind's AI makes gigantic leap in solving protein structures
    Callaway E. 'It will change everything': DeepMind's AI makes gigantic leap in solving protein structures. (2020)  Nature, 588 (7837): 203-204. [PMID:33257889]
    Outeiral C. CASP14: what Google DeepMind’s AlphaFold 2 really achieved, and what it means for protein folding, biology and bioinformatics.  Oxford Protein Informatics Group, https://www.blopig.com/blog/2020/12/casp14-what-google-deepminds-alphafold-2-really-achieved-and-what-it-means-for-protein-folding-biology-and-bioinformatics/

  • Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics.
    Walsh MA, Grimes JM, Stuart DI. Diamond Light Source: contributions to SARS-CoV-2 biology and therapeutics. (2021)  Biochem Biophys Res Commun, 538: 40-46. [PMID:33248689]

  • November 2020


  • Pathway information extracted from 25 years of pathway figures.
    Hanspers K, Riutta A, Summer-Kutmon M, Pico AR. Pathway information extracted from 25 years of pathway figures. (2020)  Genome Biol, 21 (1): 273. [PMID:33168034]

  • Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data.
    Hu J, Li C, Wang S, Li T, Zhang H. Genetic variants are identified to increase risk of COVID-19 related mortality from UK Biobank data. (2020)  medRxiv, Preprint. DOI: 10.1101/2020.11.05.20226761

  • Combinatorial expression of GPCR isoforms affects signalling and drug responses.
    Marti-Solano M, Crilly SE, Malinverni D, Munk C, Harris M, Pearce A, Quon T, Mackenzie AE, Wang X, Peng J et al.. Combinatorial expression of GPCR isoforms affects signalling and drug responses. (2020)  Nature, 587 (7835): 650-656. [PMID:33149304]

  • Biogen’s Alzheimer’s drug candidate takes a beating from FDA advisers.
    Servick K. Biogen’s Alzheimer’s drug candidate takes a beating from FDA advisers. 
    Accessed on 11/11/2020. Modified on 11/11/2020. https://www.sciencemag.org/news/2020/11/biogen-s-alzheimer-s-drug-candidate-takes-beating-fda-advisers

  • Interferon deficiency can lead to severe COVID
    Bastard P, Rosen LB, Zhang Q, Michailidis E, Hoffmann HH, Zhang Y, Dorgham K, Philippot Q, Rosain J, Béziat V et al.. Autoantibodies against type I IFNs in patients with life-threatening COVID-19. (2020)  Science, 370 (6515). [PMID:32972996]
    Meffre E, Iwasaki A. Interferon deficiency can lead to severe COVID. (2020)  Nature, 587 (7834): 374-376. [PMID:33139913]
    Zhang Q, Bastard P, Liu Z, Le Pen J, Moncada-Velez M, Chen J, Ogishi M, Sabli IKD, Hodeib S, Korol C et al.. Inborn errors of type I IFN immunity in patients with life-threatening COVID-19. (2020)  Science, 370 (6515). [PMID:32972995]

  • A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research
    Zahoránszky-Kőhalmi G, Siramshetty VB, Kumar P, Gurumurthy M, Grillo B, Mathew B, Metaxatos D, Backus M, Mierzwa T, Simon R, et al.. A Workflow of Integrated Resources to Catalyze Network Pharmacology Driven COVID-19 Research. (2020)  bioRxiv, Preprint. DOI: 10.1101/2020.11.04.369041
    National Center for Advancing Translational Sciences (NCATS). Neo4COVID-19.  https://neo4covid19.ncats.io

  • COVID Moonshot: Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning.
    The COVID Moonshot Consortium. COVID Moonshot: Open Science Discovery of SARS-CoV-2 Main Protease Inhibitors by Combining Crowdsourcing, High-Throughput Experiments, Computational Simulations, and Machine Learning. (2020)  bioRxiv, Preprint. DOI: 10.1101/2020.10.29.339317

  • The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug.
    Cohen J, Kupferschmidt K. The ‘very, very bad look’ of remdesivir, the first FDA-approved COVID-19 drug. 
    Accessed on 02/11/2020. Modified on 02/11/2020. https://www.sciencemag.org/news/2020/10/very-very-bad-look-remdesivir-first-fda-approved-covid-19-drug

  • COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms.
    Ostaszewski M, Niarakis A, Mazein A, Kuperstein I, Phair R, Orta-Resendiz A, Singh V, Aghamir SS, Acencio ML, Glaab E et al.. COVID-19 Disease Map, a computational knowledge repository of SARS-CoV-2 virus-host interaction mechanisms. (2020)  bioRxiv, Preprint. DOI: 10.1101/2020.10.26.356014

  • October 2020


  • The COVID-19 Pandemic and the $16 Trillion Virus.
    Cutler DM, Summers LH. The COVID-19 Pandemic and the $16 Trillion Virus. (2020)  JAMA, 324 (15): 1495-1496. [PMID:33044484]

  • PROTAC-DB: an online database of PROTACs.
    Weng G, Shen C, Cao D, Gao J, Dong X, He Q, Yang B, Li D, Wu J, Hou T. PROTAC-DB: an online database of PROTACs. (2021)  Nucleic Acids Res, 49 (D1): D1381-D1387. [PMID:33010159]

  • The major genetic risk factor for severe COVID-19 is inherited from Neanderthals.
    Zeberg H, Pääbo S. The major genetic risk factor for severe COVID-19 is inherited from Neanderthals. (2020)  Nature, 587 (7835): 610-612. [PMID:32998156]

  • A Thalamic Orphan Receptor Drives Variability in Short-Term Memory.
    Hsiao K, Noble C, Pitman W, Yadav N, Kumar S, Keele GR, Terceros A, Kanke M, Conniff T, Cheleuitte-Nieves C et al.. A Thalamic Orphan Receptor Drives Variability in Short-Term Memory. (2020)  Cell, 183 (2): 522-536.e19. [PMID:32997977]

  • Disease trajectory browser for exploring temporal, population-wide disease progression patterns in 7.2 million Danish patients.
    Siggaard T, Reguant R, Jørgensen IF, Haue AD, Lademann M, Aguayo-Orozco A, Hjaltelin JX, Jensen AB, Banasik K, Brunak S. Disease trajectory browser for exploring temporal, population-wide disease progression patterns in 7.2 million Danish patients. (2020)  Nat Commun, 11 (1): 4952. [PMID:33009368]

  • September 2020


  • Emerging Pandemic Diseases: How We Got to COVID-19.
    Morens DM, Fauci AS. Emerging Pandemic Diseases: How We Got to COVID-19. (2020)  Cell, 182 (5): 1077-1092. [PMID:32846157]

  • Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor.
    Kim K, Che T, Panova O, DiBerto JF, Lyu J, Krumm BE, Wacker D, Robertson MJ, Seven AB, Nichols DE et al.. Structure of a Hallucinogen-Activated Gq-Coupled 5-HT2A Serotonin Receptor. (2020)  Cell, 182 (6): 1574-1588.e19. [PMID:32946782]

  • Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening.
    Zhu W, Xu M, Chen CZ, Guo H, Shen M, Hu X, Shinn P, Klumpp-Thomas C, Michael SG, Zheng W. Identification of SARS-CoV-2 3CL Protease Inhibitors by a Quantitative High-throughput Screening. (2020)  bioRxiv,. [PMID:32803196]

  • Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19.
    Boras B, Jones RM, Anson BJ, Arenson D, Aschenbrenner L, Bakowski MA, Beutler N, Binder J, Chen E, Eng H et al.. Discovery of a Novel Inhibitor of Coronavirus 3CL Protease as a Clinical Candidate for the Potential Treatment of COVID-19. (2020)  bioRxiv,. [PMID:32935104]

  • Hot Topics: Soluble ligands as drug targets.

    Comments by Misty Attwood and Helgi Schiöth, University of Uppsala, Uppsala, Sweden. Helgi Schiöth is Chair for NC-IUPHAR Subcommitees for Melanocortin receptors and Prolactin-releasing peptide receptor.

    Historically, the main classes of drug targets have been receptors, enzymes, ion channels and transporters which are primarily targeted by small molecules. However, advances in molecular biology, genomics, and pharmacology have facilitated the development of different therapeutic modalities which in turn have broadened the types of drug targets.. Read the full article on our blog

  • August 2020


  • Computational design of transmembrane pores.
    Xu C, Lu P, Gamal El-Din TM, Pei XY, Johnson MC, Uyeda A, Bick MJ, Xu Q, Jiang D, Bai H et al.. Computational design of transmembrane pores. (2020)  Nature, 585 (7823): 129-134. [PMID:32848250]

  • Global alignment and assessment of TRP channel transmembrane domain structures to explore functional mechanisms.
    Huffer KE, Aleksandrova AA, Jara-Oseguera A, Forrest LR, Swartz KJ. Global alignment and assessment of TRP channel transmembrane domain structures to explore functional mechanisms. (2020)  Elife, 9. [PMID:32804077]

  • The Human Genome Project changed everything.
    Gibbs RA. The Human Genome Project changed everything. (2020)  Nat Rev Genet, 21 (10): 575-576. [PMID:32770171]

  • Guidelines for human gene nomenclature.
    Bruford EA, Braschi B, Denny P, Jones TEM, Seal RL, Tweedie S. Guidelines for human gene nomenclature. (2020)  Nat Genet, 52 (8): 754-758. [PMID:32747822]

  • The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3.
    Wedemeyer MJ, Mahn SA, Getschman AE, Crawford KS, Peterson FC, Marchese A, McCorvy JD, Volkman BF. The chemokine X-factor: Structure-function analysis of the CXC motif at CXCR4 and ACKR3. (2020)  J Biol Chem, 295 (40): 13927-13939. [PMID:32788219]

  • The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020.
    Liu Y, Liang C, Xin L, Ren X, Tian L, Ju X, Li H, Wang Y, Zhao Q, Liu H et al.. The development of Coronavirus 3C-Like protease (3CLpro) inhibitors from 2010 to 2020. (2020)  Eur J Med Chem, 206: 112711. [PMID:32810751]

  • Watcher in the wastewater.
    Schmidt C. Watcher in the wastewater. (2020)  Nat Biotechnol, 38 (8): 917-920. [PMID:32724212]

  • Expanded ENCODE delivers invaluable genomic encyclopedia.
    Hon CC, Carninci P. Expanded ENCODE delivers invaluable genomic encyclopedia. (2020)  Nature, 583 (7818): 685-686. [PMID:32728235]

  • A Coordinated Approach by Public Domain Bioinformatics Resources to Aid the Fight Against Alzheimer's Disease Through Expert Curation of Key Protein Targets.
    Breuza L, Arighi CN, Argoud-Puy G, Casals-Casas C, Estreicher A, Famiglietti ML, Georghiou G, Gos A, Gruaz-Gumowski N, Hinz U et al.. A Coordinated Approach by Public Domain Bioinformatics Resources to Aid the Fight Against Alzheimer's Disease Through Expert Curation of Key Protein Targets. (2020)  J Alzheimers Dis, 77 (1): 257-273. [PMID:32716361]

  • How does SARS-CoV-2 cause COVID-19?.
    Matheson NJ, Lehner PJ. How does SARS-CoV-2 cause COVID-19?. (2020)  Science, 369 (6503): 510-511. [PMID:32732413]

  • July 2020


  • RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery.
    Zhu W, Chen CZ, Gorshkov K, Xu M, Lo DC, Zheng W. RNA-Dependent RNA Polymerase as a Target for COVID-19 Drug Discovery. (2020)  SLAS Discov, 25 (10): 1141-1151. [PMID:32660307]

  • Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing.
    Riva L, Yuan S, Yin X, Martin-Sancho L, Matsunaga N, Pache L, Burgstaller-Muehlbacher S, De Jesus PD, Teriete P, Hull MV et al.. Discovery of SARS-CoV-2 antiviral drugs through large-scale compound repurposing. (2020)  Nature, 586 (7827): 113-119. [PMID:32707573]

  • Benchmarking Data Sets from PubChem BioAssay Data: Current Scenario and Room for Improvement.
    Tran-Nguyen VK, Rognan D. Benchmarking Data Sets from PubChem BioAssay Data: Current Scenario and Room for Improvement. (2020)  Int J Mol Sci, 21 (12). [PMID:32575564]

  • Insights into genetics, human biology and disease gleaned from family based genomic studies.
    Posey JE, O'Donnell-Luria AH, Chong JX, Harel T, Jhangiani SN, Coban Akdemir ZH, Buyske S, Pehlivan D, Carvalho CMB, Baxter S et al.. Insights into genetics, human biology and disease gleaned from family based genomic studies. (2019)  Genet Med, 21 (4): 798-812. [PMID:30655598]

  • The IMEx Coronavirus interactome: an evolving map of Coronaviridae-Host molecular interactions.
    Perfetto L, Pastrello C, Del-Toro N, Duesbury M, Iannuccelli M, Kotlyar M, Licata L, Meldal B, Panneerselvam K, Panni S et al.. The IMEx Coronavirus interactome: an evolving map of Coronaviridae-Host molecular interactions. (2020)  bioRxiv, Preprint. [PMID:32587962]

  • ThermoFRET: A novel nanoscale G protein coupled receptor thermostability assay functional in crude solubilised membrane preparations.
    David N Tippett et al. ThermoFRET: A novel nanoscale G protein coupled receptor thermostability assay functional in crude solubilised membrane preparations.   bioRxiv, Preprint. DOI: 10.1101/2020.07.07.191957

  • Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.
    Jeffrey Seow et al. Longitudinal evaluation and decline of antibody responses in SARS-CoV-2 infection.   medRxiv, Preprint. DOI: 10.1101/2020.07.09.20148429

  • Structural basis of CXC chemokine receptor 2 activation and signalling.
    Liu K, Wu L, Yuan S, Wu M, Xu Y, Sun Q, Li S, Zhao S, Hua T, Liu ZJ. Structural basis of CXC chemokine receptor 2 activation and signalling. (2020)  Nature, 585 (7823): 135-140. [PMID:32610344]

  • Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor.
    Mafi A, Kim SK, Goddard 3rd WA. Mechanism of β-arrestin recruitment by the μ-opioid G protein-coupled receptor. (2020)  Proc Natl Acad Sci U S A, 117 (28): 16346-16355. [PMID:32601232]

  • June 2020


  • The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides.
    Meyrath M, Szpakowska M, Zeiner J, Massotte L, Merz MP, Benkel T, Simon K, Ohnmacht J, Turner JD, Krüger R et al.. The atypical chemokine receptor ACKR3/CXCR7 is a broad-spectrum scavenger for opioid peptides. (2020)  Nat Commun, 11 (1): 3033. [PMID:32561830]

  • Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice.
    Mock ED, Mustafa M, Gunduz-Cinar O, Cinar R, Petrie GN, Kantae V, Di X, Ogasawara D, Varga ZV, Paloczi J et al.. Discovery of a NAPE-PLD inhibitor that modulates emotional behavior in mice. (2020)  Nat Chem Biol, 16 (6): 667-675. [PMID:32393901]

  • Hot Topics: TMEM163 Regulates ATP-Gated P2X Receptor and Behavior.

    Comments by Charles Kennedy, Strathclyde Institute of Pharmacy and Biomedical Sciences, University of Strathclyde, Glasgow, UK. Chair for NC-IUPHAR Subcommitee for P2X receptors.

    It is now clear that ligand-gated ion channels (LGICs) are not "stand alone" functional units, but form complexes with other components, including scaffolding proteins, regulatory proteins and enzymes. Besides their important physiological roles, these modulating proteins are also potential targets for drug discovery. P2X receptors are LGICs for which ATP is the endogenous agonist. Seven P2X subunits have been identified and they form trimers to produce at least twelve different receptor subtypes. Here, the authors combined a genome-wide open reading frame (ORF) collection with high-throughput functional screening, to search for P2X receptor modulators [106].. Read the full article on our blog

  • Discovery of polypeptide ligand-receptor pairs based on their co-evolution.
    Hsueh AJW, Feng Y. Discovery of polypeptide ligand-receptor pairs based on their co-evolution. (2020)  FASEB J, 34 (7): 8824-8832. [PMID:32501617]

  • Agonist binding directs dynamic competition among nuclear receptors for heterodimerization with retinoid X receptor.
    Fadel L, Rehó B, Volkó J, Bojcsuk D, Kolostyák Z, Nagy G, Müller G, Simandi Z, Hegedüs É, Szabó G et al.. Agonist binding directs dynamic competition among nuclear receptors for heterodimerization with retinoid X receptor. (2020)  J Biol Chem, 295 (29): 10045-10061. [PMID:32513869]

  • Fentanyl but not Morphine Interacts with Nonopioid Recombinant Human Neurotransmitter Receptors and Transporters.
    Torralva R, Eshleman AJ, Swanson TL, Schmachtenberg JL, Schutzer WE, Bloom SH, Wolfrum KM, Reed JF, Janowsky A. Fentanyl but not Morphine Interacts with Nonopioid Recombinant Human Neurotransmitter Receptors and Transporters. (2020)  J Pharmacol Exp Ther, 374 (3): 376-391. [PMID:32513839]

  • Cryo-EM structures of inactive and active GABAB receptor.
    Mao C, Shen C, Li C, Shen DD, Xu C, Zhang S, Zhou R, Shen Q, Chen LN, Jiang Z et al.. Cryo-EM structures of inactive and active GABAB receptor. (2020)  Cell Res, 30 (7): 564-573. [PMID:32494023]

  • Does In Vitro Potency Predict Clinically Efficacious Concentrations?.
    Jansson-Löfmark R, Hjorth S, Gabrielsson J. Does In Vitro Potency Predict Clinically Efficacious Concentrations?. (2020)  Clin Pharmacol Ther, 108 (2): 298-305. [PMID:32275768]

  • Evaluating drug targets through human loss-of-function genetic variation.
    Minikel EV, Karczewski KJ, Martin HC, Cummings BB, Whiffin N, Rhodes D, Alföldi J, Trembath RC, van Heel DA, Daly MJ et al.. Evaluating drug targets through human loss-of-function genetic variation. (2020)  Nature, 581 (7809): 459-464. [PMID:32461653]

  • May 2020


  • Hot Topics: A trio of GPCR peptide publications

    Comments by Chris Southan, Fellow of the University Edinburgh, Owner of TW2Informatics , Chair of NC-IUPHAR Subcommitees for Proteases and Drug Targets and Chemistry (DRUTACS).

    This post covers three recent publications with a common theme and whose authors are collaborators with GtoPdb, thus making them as a trio particularly suitable for combined review. These are; Discovery of Human Signaling Systems: Pairing Peptides to G Protein-Coupled Receptors [41], Novel approaches leading towards peptide GPCR de-orphanisation [54], and Advances in therapeutic peptides targeting G protein-coupled receptors (see Davenport et al., 2020). As expected, these are all clearly written, contain valuable detail and each includes its own introduction. Therefore this piece does not need to go over these works per se but simply point out their coverage, domain of application, along with brief explanations of entity linking and/or external look-up options.. Read the full article on our blog

  • 15 drugs being tested to treat COVID-19 and how they would work.
    Shaffer L. 15 drugs being tested to treat COVID-19 and how they would work. (2020)  Nat Med, [Epub ahead of print]. [PMID:32415251]

  • Structure of replicating SARS-CoV-2 polymerase.
    Hillen HS, Kokic G, Farnung L, Dienemann C, Tegunov D, Cramer P. Structure of replicating SARS-CoV-2 polymerase. (2020)  Nature, 584 (7819): 154-156. [PMID:32438371]

  • Construction of a human cell landscape at single-cell level.
    Han X, Zhou Z, Fei L, Sun H, Wang R, Chen Y, Chen H, Wang J, Tang H, Ge W et al.. Construction of a human cell landscape at single-cell level. (2020)  Nature, 581 (7808): 303-309. [PMID:32214235]

  • Connecting data, tools and people across Europe: ELIXIR's response to the COVID-19 pandemic.
    Blomberg N, Lauer KB. Connecting data, tools and people across Europe: ELIXIR's response to the COVID-19 pandemic. (2020)  Eur J Hum Genet, 28 (6): 719-723. [PMID:32415272]

  • Novel approaches and current challenges with targeting the endocannabinoid system.
    Morales P, Jagerovic N. Novel approaches and current challenges with targeting the endocannabinoid system. (2020)  Expert Opin Drug Discov, 15 (8): 917-930. [PMID:32336154]